The specialist drug development Company, delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, has announced amended terms to the 2016 licensing agreement between Sierra Oncology and CRT Pioneer Fund LP (CPF) for the Chk1 inhibitor SRA737.
12 Nov 2020
Could Sierra be looking to push forward with SRA 737?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Could Sierra be looking to push forward with SRA 737?
Sareum Holdings plc (SAR:LON) | 11.0 -0.4 (-24.1%) | Mkt Cap: 7.89m
- Published:
12 Nov 2020 -
Author:
Derren Nathan -
Pages:
7
The specialist drug development Company, delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, has announced amended terms to the 2016 licensing agreement between Sierra Oncology and CRT Pioneer Fund LP (CPF) for the Chk1 inhibitor SRA737.